Cas no 39562-70-4 (Nitrendipine)
Nitrendipine Chemical and Physical Properties
Names and Identifiers
-
- Nitrendipine
- ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(meta-nitrophenyl)-3,5-pyridinedicarboxylate
- 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
- BAY-E-5009
- Bylotensin
- BAY E 5009
- Bayotensin
- Baypress
- Nidrel
- Nitrendipinum
- Nitrendipin
- Nitrendipino
- Deiten
- Nitrendipinum [INN-Latin]
- Nitrendipino [INN-Spanish]
- 3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- MLS000069349
- PVHUJELLJLJGLN-UHFFFAOYSA-N
- C18H20N2O6
- 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophe
- SR-01000075334-2
- PD033036
- MLS002154060
- A824621
- NITRENDIPINE [EP IMPURITY]
- Nitrendipine, European Pharmacopoeia (EP) Reference Standard
- HMS2089H15
- EINECS 254-513-1
- UNII-9B627AW319
- (+/-)-ETHYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
- SCHEMBL38972
- SPBio_001470
- HMS3411I14
- Bio1_001098
- HMS1570H14
- Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
- 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (.+/-.)-
- (.+/-.)-Nitrendipine
- NCGC00261566-01
- Nitrendipine [USAN:INN:BAN:JAN]
- NC00241
- Pharmakon1600-01503609
- Nitrepin
- SMR000058366
- NCGC00024676-06
- HMS3675I14
- D00629
- Spectrum5_001655
- 9B627AW319
- CHEMBL3195219
- Prestwick0_000916
- methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- (+/-)-NITRENDIPINE
- AKOS015894921
- Bio2_000599
- Spectrum_001901
- SR-01000075334-6
- NCGC00015713-13
- SW219737-1
- W-106422
- Baylotensin
- NSC 758466
- NCGC00015713-07
- KBioSS_000119
- Nitrendipine,(S)
- BRD-A02006392-001-09-9
- N1186
- NITRENDIPINE [MART.]
- NITRENDIPINE [EP MONOGRAPH]
- NCGC00015713-26
- KBioGR_000119
- ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- Bio1_000120
- KBioSS_002432
- AKOS016340326
- NCGC00015713-04
- AC-648
- KBio1_001782
- NCGC00024013-02
- NITRENDIPINE [INN]
- HMS2097H14
- N-144
- BRD-A02006392-001-06-5
- MLS001424133
- SpecPlus_000742
- Nitrendipine, >95%, powder
- NSC758466
- NCGC00024676-03
- 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (+-)-
- HMS2051B04
- HMS3714H14
- HMS2230F04
- HMS3262B04
- HMS1791F21
- HMS3402F21
- CBiol_001834
- CCG-100991
- Prestwick2_000916
- NCGC00015713-05
- NCGC00024676-07
- 39562-70-4
- NITRENDIPINE [WHO-DD]
- Nitrendipine 100 microg/mL in Acetonitrile
- BPBio1_000872
- Z239859926
- AKOS000622913
- 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-ethyl 5-methyl ester
- C07713
- O3-ethyl O5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- AB00053154_04
- SR-01000075334
- FT-0601600
- 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylic acid ethyl methyl ester
- MLS001148149
- BRD-6392
- KBio2_002426
- AB00053154_05
- Prestwick3_000916
- BRD6392
- (+-)-Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
- Nitrendipine (JP17/USAN/INN)
- Spectrum2_001565
- AB00513962
- EN300-18434855
- 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (+/-)-
- 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid ethyl methyl ester
- NCGC00015713-09
- KBio2_002687
- HMS2093G17
- Lopac0_000881
- KBioGR_001476
- KBio2_000119
- CCG-39343
- Ethyl 1,4-dihydro-5-(acetoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridincarboxylat
- IDI1_033869
- KS-1305
- Baypress (TN)
- Spectrum4_001088
- NCGC00024676-05
- DTXSID0023373
- BSPBio_002575
- KBio3_000237
- NITRENDIPINE [JAN]
- HMS1989F21
- HMS1361F21
- DTXCID203373
- EU-0100881
- KBio3_001795
- NITRENDIPINE [MI]
- SR-01000075334-1
- Tox21_110201
- CAS-39562-70-4
- SR-01000075334-4
- NCGC00015713-10
- NCGC00024676-04
- CA-212
- 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester
- NCGC00015713-06
- GTPL2334
- SPECTRUM1503609
- Nitrendipine for peak identification
- HMS3884H21
- Opera_ID_928
- Oprea1_472855
- (.+/-.)-Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
- NCGC00015713-08
- MFCD00082255
- KBio2_007562
- Spectrum3_000968
- CHEBI:7582
- DB01054
- 3-Ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #
- Tox21_110201_1
- HMS3393B04
- NCGC00024676-02
- NSC-758466
- Prestwick1_000916
- BSPBio_001399
- HMS3266B03
- Tox21_500881
- LP00881
- Ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate
- AB00053154-03
- NITRENDIPINE [USAN]
- HMS3651F05
- BSPBio_000792
- PD003069
- SY058769
- DivK1c_006838
- SBI-0050856.P003
- 3-ethyl5-methyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- Bio2_000119
- HY-B0424
- Nitrendipine for peak identification, European Pharmacopoeia (EP) Reference Standard
- BCP07540
- BDBM50237611
- SPBio_002981
- Q416584
- HMS3371J07
- (+/-)-BAY-E-5009
- SDCCGSBI-0050856.P004
- MLS002153303
- NCGC00015713-11
- MLS000759400
- Bio1_000609
- KBio2_004994
- KBio3_000238
- S2491
- Oprea1_703261
- NS00007571
- BRN 0498823
- KBio2_005255
- A10804
- STK368903
- Nitrendipine (JP18/USAN/INN)
- 1ST10230
- BRD-A02006392-001-17-2
- BBL028163
- BRD-A02006392-001-15-6
- BRD-A02006392-001-16-4
-
- MDL： MFCD00082255
- Inchi： 1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
- InChI Key： PVHUJELLJLJGLN-UHFFFAOYSA-N
- SMILES： O(CC)C(C1=C(C)NC(C)=C(C(=O)OC)C1C1C=CC=C(C=1)[N+](=O)[O-])=O
- BRN： 0498823
Computed Properties
- Exact Mass: 360.13200
- Monoisotopic Mass: 360.132
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 26
- Rotatable Bond Count: 6
- Complexity: 661
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 5
- XLogP3: 2.9
- Topological Polar Surface Area: 110
Experimental Properties
- Color/Form: Yellow powder
- Density: 1.3595 (rough estimate)
- Melting Point: 158°C
- Boiling Point: 464.8℃/760mmHg
- Flash Point: 249.5±28.7 °C
- Refractive Index: 1.5700 (estimate)
- Solubility: methanol: 15?mg/mL
- Water Partition Coefficient: Soluble in DMSO (17.5 mg/ml), methanol (15 mg/ml), ethyl acetate, and ethanol (25 mM). Insoluble in water.
- PSA: 110.45000
- LogP: 3.41770
- Solubility: It is easily soluble in acetone or chloroform, slightly soluble in methanol or ethanol, and almost insoluble in water.
Nitrendipine Security Information
-
Symbol:
- Signal Word：Warning
- Hazard Statement： H312,H332
- Warning Statement： P280
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：1
- Hazard Category Code： 20/21/22
- Safety Instruction： S36
- RTECS：US5653000
-
Hazardous Material Identification：
- Safety Term：S36
- Toxicity：LD50 in mice, rats (mg/kg): 39, 12.6 i.v.; 2540, >10000 orally (Hoffmann)
- Storage Condition：4°C, protect from light
- Risk Phrases：R20/21/22
Nitrendipine Customs Data
- HS CODE：2933399090
- Customs Data：
China Customs Code:
2933399090Overview:
2933399090. Other compounds with non fused pyridine rings in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Nitrendipine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| YUN NAN XI LI SHENG WU JI SHU GU FEN Co., Ltd. | BBP80164-5mg |
Nitrendipine |
39562-70-4 | 98.0% | 5mg |
￥100 | 2021-05-07 | |
| MedChemExpress | HY-B0424-10mM*1mLinDMSO |
Nitrendipine |
39562-70-4 | 99.48% | 10mM*1mLinDMSO |
￥847 | 2023-07-26 | |
| MedChemExpress | HY-B0424-50mg |
Nitrendipine |
39562-70-4 | 99.48% | 50mg |
￥770 | 2025-04-16 | |
| MedChemExpress | HY-B0424-100mg |
Nitrendipine |
39562-70-4 | 99.48% | 100mg |
￥1221 | 2025-04-16 | |
| MedChemExpress | HY-B0424-200mg |
Nitrendipine |
39562-70-4 | 99.48% | 200mg |
￥1863 | 2025-04-16 | |
| MedChemExpress | HY-B0424-500mg |
Nitrendipine |
39562-70-4 | 99.48% | 500mg |
￥3400 | 2025-04-16 | |
| MedChemExpress | HY-B0424-1g |
Nitrendipine |
39562-70-4 | 99.48% | 1g |
￥4671 | 2025-04-16 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R001515-1g |
Nitrendipine |
39562-70-4 | 95% | 1g |
￥108 | 2023-09-09 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R001515-100mg |
Nitrendipine |
39562-70-4 | 95% | 100mg |
￥31 | 2023-09-09 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R001515-500mg |
Nitrendipine |
39562-70-4 | 95% | 500mg |
￥78 | 2023-09-09 |
Nitrendipine Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Nitrendipine Related Literature
-
Shiping Zhan,Jingchang Wang,Weijing Wang,Liyun Cui,Qicheng Zhao RSC Adv. 2019 9 16167
-
You Li,Ji Li,Shanqiao Chen,Dan Yang,Chengchu Liu,Guorong Fan Anal. Methods 2013 5 3353
-
N. Poovaiah,Z. Davoudi,H. Peng,B. Schlichtmann,S. Mallapragada,B. Narasimhan,Q. Wang Nanoscale 2018 10 16962
-
Alyne Fávero Galv?o,Tatiana Okura Ajimura,Fernando Armani Aguiar,Keyller Bastos Borges,Cristiane Masetto de Gaitani Anal. Methods 2012 4 2953
-
Xiuling Tang,Huanhuan Zhao,Wei Jiang,Song Zhang,Shun Guo,Xiaobo Gao,Peng Yang,Lei Shi,Linna Liu Food Funct. 2018 9 5880
Additional information on Nitrendipine
Introduction to Nitrendipine (CAS No. 39562-70-4)
Nitrendipine, a calcium channel blocker, is a pharmaceutical compound with the chemical formula C??H??N?O?. Its CAS number, 39562-70-4, uniquely identifies it in the chemical and pharmaceutical industries. This compound has garnered significant attention due to its therapeutic applications and the ongoing research that continues to explore its potential benefits.
The primary mechanism of action for Nitrendipine involves its selective binding to L-type calcium channels in cardiac and vascular smooth muscle cells. By blocking these channels, it reduces the influx of calcium ions, leading to vasodilation and decreased blood pressure. This mechanism makes it particularly effective in the management of hypertension and angina pectoris.
Recent studies have highlighted the therapeutic potential of Nitrendipine in conditions beyond cardiovascular disorders. For instance, research has suggested that it may have neuroprotective properties, making it a candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound's ability to cross the blood-brain barrier has opened new avenues for investigation in central nervous system disorders.
In clinical settings, Nitrendipine is often prescribed for its efficacy in lowering blood pressure and alleviating symptoms associated with coronary artery disease. Its long half-life allows for once-daily dosing, improving patient compliance. The drug's safety profile has been well-documented, with common side effects including dizziness, headache, and edema, which are generally manageable and dose-dependent.
Advances in pharmacokinetic studies have provided deeper insights into how Nitrendipine interacts with biological systems. Researchers have utilized techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy to elucidate its metabolic pathways. These findings have been crucial in optimizing dosing regimens and identifying potential drug-drug interactions.
The development of novel formulations of Nitrendipine has also been a focus of recent research. Transdermal patches and extended-release tablets have been explored to enhance bioavailability and reduce gastrointestinal side effects. Such innovations aim to improve patient comfort while maintaining therapeutic efficacy.
Emerging evidence suggests that Nitrendipine may have anti-inflammatory properties, which could be beneficial in conditions like rheumatoid arthritis. Preclinical studies have demonstrated its ability to modulate inflammatory pathways, potentially opening new therapeutic strategies for autoimmune diseases.
The role of Nitrendipine in combination therapy has also been investigated. Studies have shown that when used in conjunction with ACE inhibitors or beta-blockers, it can provide synergistic effects in managing cardiovascular conditions. This underscores the importance of personalized medicine approaches in optimizing treatment outcomes.
Future research directions for Nitrendipine include exploring its potential as an adjunct therapy in cancer treatment. Preliminary studies have indicated that it may inhibit tumor growth by interfering with calcium signaling pathways in cancer cells. While further investigation is needed, these findings hold promise for developing new anticancer strategies.
The global market for Nitrendipine continues to grow, driven by increasing prevalence of cardiovascular diseases and advancements in drug delivery systems. Pharmaceutical companies are investing heavily in research to expand its therapeutic applications and improve patient outcomes.
In conclusion, Nitrendipine (CAS No. 39562-70-4) is a versatile pharmaceutical compound with a well-established role in cardiovascular therapy. Its unique properties and ongoing research make it a promising candidate for treating a wide range of conditions, from hypertension to neurodegenerative diseases. As scientific understanding continues to evolve, the therapeutic potential of Nitrendipine is expected to expand further, offering new hope for patients worldwide.
39562-70-4 (Nitrendipine) Related Products
- 499-81-0(3,5-Pyridinedicarboxylic Acid)
- 39562-22-6(2-Methoxyethyl 2-(3-Nitrobenzylidene)acetoacetate)
- 66085-59-4(Nimodipine)
- 22502-03-0(2-Methoxyethyl acetoacetate)
- 21829-25-4(Nifedipine)
- 62571-86-2(Captopril)
- 100427-26-7(Lercanidipine)
- 14205-46-0(Isopropyl 3-aminocrotonate)
- 22609-73-0(Niludipine)
- 21881-77-6(M-Nifedipine)
